Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure
Authors:
- Xian Wu ChengXCXian Wu Cheng
- Koji ObataKOKoji Obata
- Masafumi KuzuyaMKMasafumi Kuzuya
- Hideo IzawaHIHideo Izawa
- Kae NakamuraKNKae Nakamura
- Eri AsaiEAEri Asai
- Tetsuro NagasakaTNTetsuro Nagasaka
- Masako SakaMSMasako Saka
- Takahiro KimataTKTakahiro Kimata
- Akiko NodaANAkiko Noda
- Kohzo NagataKNKohzo Nagata
- Hai JinHJHai Jin
- 1 November 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 48 (5) , 979-987
Abstract
Cathepsins are cysteine proteases that participate in various types of tissue remodeling. However, their expressions during myocardial remodeling have not been examined. In this study, we investigated their expressions in the left ventricular (LV) myocardium of rats and humans with hypertension-induced LV hypertrophy or heart failure (HF). Real-time PCR and immunoblot analysis revealed that the abundance of cathepsin S mRNA or protein in the LV tissues was greater in rats or humans with HF than in those with hypertrophy or in control subjects. Immunostaining showed that cathepsin S was localized predominantly to cardiac myocytes and coronary vascular smooth muscle cells, but also overlapped in part with macrophages. Elastic lamina fragmentations significantly increased in the LV intramyocardial coronary arteries of HF rats. The amount of elastolytic activity in the extract of the LV myocardium was markedly increased for HF rats compared with controls, and this activity was mostly because of cathepsin S. Although the amount of elastin mRNA was increased in the LV myocardium of HF rats, the area of interstitial elastin was not. The expression of interleukin 1β was increased in the LV myocardium of HF rats, and this cytokine was found to increase the expression and activity of cathepsin S in cultured neonatal cardiomyocytes. These results suggest that cathepsin S participates in pathological LV remodeling associated with hypertension-induced HF. This protease is, thus, a potential target for therapeutics aimed at preventing or reversing cardiac remodeling.Keywords
This publication has 40 references indexed in Scilit:
- Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive RatsHypertension, 2006
- Localization of Cysteine Protease, Cathepsin S, to the Surface of Vascular Smooth Muscle Cells by Association with Integrin ανβ3The American Journal of Pathology, 2006
- Lack of the Cysteine Protease Inhibitor Cystatin C Promotes Atherosclerosis in Apolipoprotein E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Cystatin C, a Novel Measure of Renal Function, Is an Independent Predictor of Cardiac Events in Patients With Heart FailureJournal of Cardiac Failure, 2005
- Aldosterone Stimulates Matrix Metalloproteinases and Reactive Oxygen Species in Adult Rat Ventricular CardiomyocytesHypertension, 2005
- Cystatin C Deficiency Increases Elastic Lamina Degradation and Aortic Dilatation in Apolipoprotein E–Null MiceCirculation Research, 2005
- Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in MiceThe American Journal of Pathology, 2005
- Estimation of glomerular filtration rate in the elderly: a comparison of creatinine‐based formulae with serum cystatin CJournal of Internal Medicine, 2004
- AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart FailureHypertension, 2004
- Effects of Matrix Metalloproteinase Inhibition on Ventricular Remodeling Due to Volume OverloadCirculation, 2002